A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer

Recruiting now

Conditions studied: Non Small Cell Lung Cancer

In brief

In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutations.

Key facts

Study ID

NCT04777175

Run by

Yongchang Zhang

People needed

186

Starts

2023-01-01

Expected to finish

2025-01-12

Last updated by the study team

2024-09-19

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1.Diagnosed as advanced non-small cell lung cancer
• 2.Confirmed as KARS, ALK, ERBB2, MET, RET, BRAF mutation

You may not qualify if…

• The patient is diagnosed with small cell lung cancer

Where it is running

• Hunan Cancer Hospital — Changsha, Hunan, China (enrolling)
• Hunan Cancer hospital — Changsha, Hunan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.